Compañía Recauda $80 Millones para Desarrollar un Tratamiento para la Fibrosis Quística Relacionada con Mutaciones Raras

De acuerdo a una historia de Fierce Biotech, recientemente ha habido algunos avances impresionantes en el tratamiento de la fibrosis quística. El último hito fue desarrollar y aprobar el medicamento…

Continue Reading Compañía Recauda $80 Millones para Desarrollar un Tratamiento para la Fibrosis Quística Relacionada con Mutaciones Raras
Coronavirus: Could Medical Rationing Put the Chronically Ill/Disabled in Danger?
source: pixabay.com

Coronavirus: Could Medical Rationing Put the Chronically Ill/Disabled in Danger?

In a story written for The Washington Post, Jessica Slice writes about a frightful predicament for patients with chronic illnesses that cause disability. Jessica lives with dysautonomia and hypermobile Ehlers-Danlos…

Continue Reading Coronavirus: Could Medical Rationing Put the Chronically Ill/Disabled in Danger?
FDA Approves a Treatment for Neurofibromatosis Type 1 for the First Time Ever
source: pixabay.com

FDA Approves a Treatment for Neurofibromatosis Type 1 for the First Time Ever

A press release from the US Food and Drug Administration (FDA) recently announced the approval of the drug selumetinib (marketed as Koselugo) for the treatment of patients aged two years…

Continue Reading FDA Approves a Treatment for Neurofibromatosis Type 1 for the First Time Ever
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment
source: pixabay.com

FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment

According to a story from globenewswire.com, the biopharmaceutical company Liquidia Technologies, Inc. just announced that the company's New Drug Application (NDA) has been officially accepted by the US Food and…

Continue Reading FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment
Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment
source: pixabay.com

Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment

According to a story from gurufocus.com, the biotechnology company Capricor Therapeutics has recently announced the initiation of a compassionate use program for its experimental drug CAP-1002. This drug will be…

Continue Reading Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment
Study Confirms Effectiveness of Gamma Knife Surgery for Intracanalicular Vestibular Schwannoma
source: pixabay.com

Study Confirms Effectiveness of Gamma Knife Surgery for Intracanalicular Vestibular Schwannoma

According to a study published in January in the scientific journal Acta Neurologica Scandinavica, the use of gamma knife surgery as a treatment for a rare tumor called a vestibular schwannoma can…

Continue Reading Study Confirms Effectiveness of Gamma Knife Surgery for Intracanalicular Vestibular Schwannoma
April is Parkinson’s Disease Awareness Month. Here’s How You Can Get Involved
source: pixabay.com

April is Parkinson’s Disease Awareness Month. Here’s How You Can Get Involved

The month of April is recognized as Parkinson's Disease Awareness Month. While Parkinson's disease is not considered rare, Patient Worthy chooses to continue to provide coverage of this illness because…

Continue Reading April is Parkinson’s Disease Awareness Month. Here’s How You Can Get Involved